Meet Our Investors
Anaveon is backed by more than 146 million CHF (€140 million) of funding, enabling us to develop an interleukin-2 (IL-2) agonist that has the potential to save patients’ lives.
Our funding includes a 150 thousand CHF award from BaseLaunch, a 1 million CHF convertible loan from University of Zurich Life Sciences Fund and 35 million CHF in Series A funding led by Syncona and joined by the Novartis Venture Fund. Furthermore, Anaveon agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Its vision is to build a sustainable, diverse portfolio of 15-20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which it seeks to deliver strong risk-adjusted returns for shareholders. Syncona’s aim is to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
Novartis Venture Fund
Novartis Venture Fund is a financially driven corporate life science venture fund whose purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies at various stages of their development.
UZH Life Sciences Fund
The UZH Life Sciences Fund AG (UZH LSF) invests in life science spin-offs from the University of Zurich (UZH) that are in an early stage of development. This accelerates the transfer of research results from the UZH into practice. The UZH LSF is a funding instrument established jointly by the UZH Foundation and the Novartis Venture Fund in 2016.
BaseLaunch is a venture creation and development platform that helps scientists and entrepreneurs launch and build exceptional biotech companies from inception through to Series A funding, providing financing and supporting all aspects of business development. Since 2018, BaseLaunch supported ventures have raised in total over USD 100 million. Operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency of the Basel Area, BaseLaunch partners with leading global pharma companies and venture funds.